CD19-specific CAR T cells induced complete and lasting remission of refractory CD19+ B-cell chronic lymphocytic leukemia (CLL) in all of the first three reported patients (44, 45). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.